Carbon footprint impact of the choice of inhalers for asthma and COPD
Carbon footprint impact of the choice of inhalers for asthma and COPD
复制标题
DOI：
10.1136/thoraxjnl-2019-213744
复制
发表时间：
2020-01-01
期刊：
影响因子：
10
通讯作者：
Wilkinson, Alexander J. K.
中科院分区：
文献类型：
--
作者：
Janson, Christer;Henderson, Richard;Wilkinson, Alexander J. K.
1990年代，含有氯氟烃的计量吸入器被含有氢氟烃的干粉吸入器和计量吸入器所取代。虽然氢氟碳化物不会消耗臭氧，但它们是强有力的温室气体。每名患者的年碳足迹(CO(2)e)：Relvar-Ellipta/Ventolin-Accuhaler为17 kg；Seretie-Evohaler/Ventolin-Evohaler为439 kg。2017年，英国销售的所有吸入器中有70%是MDI，而瑞典为13%。将瑞典的DPI和计量吸入器分配应用到英国将导致每年减少550kt的CO(2)e。在选择吸入器时，应将DPI的较低碳足迹与其他因素一起考虑。
In the 1990s, metered dose inhalers (MDIs) containing chlorofluorocarbons were replaced with dry-powder inhalers (DPIs) and MDIs containing hydrofluorocarbons (HFCs). While HFCs are not ozone depleting, they are potent greenhouse gases. Annual carbon footprint (CO(2)e), per patient were 17 kg for Relvar-Ellipta/Ventolin-Accuhaler; and 439 kg for Seretide-Evohaler/Ventolin-Evohaler. In 2017, 70% of all inhalers sold in England were MDI, versus 13% in Sweden. Applying the Swedish DPI and MDI distribution to England would result in an annual reduction of 550 kt CO(2)e. The lower carbon footprint of DPIs should be considered alongside other factors when choosing inhalation devices.